Creating an Efficient Clinical Trial Build System Via the Clinical Trials Rapid Activation Consortium (CTRAC)

Information

  • Research Project
  • 10227319
  • ApplicationId
    10227319
  • Core Project Number
    P30CA006516
  • Full Project Number
    3P30CA006516-56S4
  • Serial Number
    006516
  • FOA Number
    PA-18-591
  • Sub Project Id
  • Project Start Date
    3/10/1997 - 27 years ago
  • Project End Date
    11/30/2021 - 2 years ago
  • Program Officer Name
    PTAK, KRZYSZTOF
  • Budget Start Date
    9/17/2020 - 3 years ago
  • Budget End Date
    11/30/2021 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    56
  • Suffix
    S4
  • Award Notice Date
    9/17/2021 - 2 years ago

Creating an Efficient Clinical Trial Build System Via the Clinical Trials Rapid Activation Consortium (CTRAC)

Program Director/Principal Investigator (Last, First, Middle): Glimcher, Laurie H. Project Summary Standard-of-care electronic health records (EHR) treatment plans are constructed once prior to implementation and support quality through standardization. By comparison, treatment-plan builds for clinical trials may support as few as zero trial participants, must be built from the ground up for each new trial and at each added site, and have treatment plans that often require configurations for novel medications, numerous ancillary procedures, and research finance requirements. The current paradigm is costly, complex, and inefficient. Representatives of five cancer centers agreed to be part of the project?s Clinical Trials Rapid Activation Consortium (CTRAC). The project?s goal is to develop processes across multiple NCI-supported cancer centers that will facilitate the development of single builds of EHR clinical-trial treatment plans that can be deployed at multiple institutions in support of NCI- sponsored network studies. Members will investigate the question: can a small consortium of clinical trials sites develop methods to standardize workflows, drug formularies, drug administration procedures, and laboratory requirements leading to the creation of the components for a standardized, electronic, clinical-trials build system? Specific aims are as follows: 1) To identify the tasks currently performed by EHR investigational treatment plans (SOPs, policies, and workflows) and to define differences among these SOPs at the individual member sites of the consortium; 2) To standardize the processes within each task where possible and document differences that would require modifications across sites; 3) To develop a master assessment of EHR treatment-plan modules that could be reused to perform components of the same research protocol tasks at multiple sites while maintaining compliance with the requirements of member organizations of the consortium; 4) To organize a leadership structure for the consortium that will work with the NCI and an EHR provider to oversee this initiative to assure that adequate progress is made toward the ultimate goal of creating a fully automated electronic clinical-trial build system that will facilitate the activation of clinical trials across all NCI-supported networks; 5) To build standardized electronic clinical-trial build modules that could undergo future pilot testing at each institution for a specified group of NCI-sponsored clinical trials; and 6) To facilitate development of metrics for the new EHR processes that can demonstrate whether more consistent patient care, reduced medication errors, and fewer adverse events result from a standardized approach to clinical-trial build modules. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    P30
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
    169401
  • Indirect Cost Amount
    132133
  • Total Cost
    301534
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    397
  • Ed Inst. Type
  • Funding ICs
    NCI:301534\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    NCI
  • Study Section Name
    Subcommittee I - Transistion to Independence
  • Organization Name
    DANA-FARBER CANCER INST
  • Organization Department
  • Organization DUNS
    076580745
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    022155450
  • Organization District
    UNITED STATES